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acetoacetate hydrolase” (italics added) should have been writ-
ten as fumarylacetoacetate hydrolase (encoded by the FAH
gene). The chapter ends with the most recent concepts on how
to generate knockout and other transgenic mouse lines and on
how to use “quantitative trait linkage (QTL) mapping” in the
elucidation of pharmacogenetic disorders. These discussions
are absolutely first-rate.
Part II of the book is almost twice as long as part I. Each
chapter and section in part II is followed by short exercises
designed to demonstrate a pharmacogenetic principle or to
illustrate the application of concepts and techniques to phar-
macological problems; these exercises are drawn almost en-
tirely from observations (taken from the original literature)
representing authentic clinical situations.
On the whole, part II is excellent. It is a bit disappointing,
however, that, although the P450 cytochromes are discussed
at some length (pp. 131–133 and elsewhere), there are no
references citing the well-developed CYP gene–superfamily no-
menclature system or the continuously updated Website (http:
//drnelson.utmem.edu/homepage.html) on this subject. It also
is unfortunate that the CYP2D6 alleles “A, B, C, D, L,” et
cetera (p. 169) are described in this book published in 1997,
because a recommended standardized nomenclature system for
all the human CYP2D6 alleles was reported in early 1996 and
has already become widely accepted. Furthermore, it would
have been helpful to the student reader to learn that aldos-
terone synthase and steroid 11-b-hydroxylase (under “Glu-
cocorticoid-Remediable Aldosteronism,” pp. 222–225) are in
fact P450 cytochromes encoded by the CYP11B2 and
CYP11B1 genes, respectively.
It always has been debatable as to where to draw the line
regarding inclusion or exclusion of a human disease as a phar-
macogenetic defect. For example, if pyridoxine-responsive ane-
mia, fructose intolerance, and lactose intolerance are included
as “pharmacogenetic disorders,” then why not acatalasemia,
ceruloplasmin deficiency (Wilson disease), and Na-sensitive
hypertension? Likewise, cystic fibrosis, vasopressin resistance,
retinoic acid resistance/acute promyelocytic leukemia, and
thrombophilia are included in the book, whereas other dis-
orders (e.g., the CYP2A6-mediated coumarin 7-hydroxylase,
NAD(P)H:quinone oxidoreductase, and microsomal epoxide
hydrolase polymorphisms) are not included.
Last, I believe that the textbook could have been improved
if the reader had been given the opportunity to ponder why,
on an evolutionary basis, these human pharmacogenetic poly-
morphisms might have occurred in the first place (see Nebert
1997 and the references therein). It is now very clear that
DMEs and the DME receptors that control the levels of DMEs
first evolved for critical life functions (e.g., cell division, spor-
ulation, mating, homeostasis, electrolyte balance, differentia-
tion, apoptosis, and neuroendocrine functions); then, in ani-
mals, DMEs more recently expanded to include the role of
detoxification of dietary products, evolving plant metabolites
and, of course, drugs. Hence, the high allelic frequencies seen
for many DME genes, among individuals within any one ethnic
group, might represent the evolution of balanced polymor-
phisms that we presently cannot appreciate, such as improved
rates of implantation, prenatal growth and development, post-
natal health in response to dietary selective pressures, or even
resistance to bacterial or viral infections. Allelic frequencies in
DME genes that differ among ethnic groups also might reflect
differences in diet that have evolved over thousands of years.
Two recent examples of clinical diseases correlated with mu-
tations in a DME gene (encoding enzymes that have been com-
monly ascribed only to metabolizing drugs and other foreign
chemicals) further underscore the tenet that DMEs often mod-
ulate critical life processes. Mutations and deletions in the
microsomal aldehyde-dehydrogenase gene called “fatty-alde-
hyde dehydrogenase” (FALDH) have been shown to be the
cause of Sjo¨gren-Larsson syndrome, which is characterized by
mental retardation, spasticity, and ichthyosis, indicating the
importance of this enzyme in neurocutaneous homeostasis.
Mutations in the CYP1B1 gene appear to be responsible for
primary congenital glaucoma (buphthalmos), implying that
failure of the CYP1B1 enzyme to metabolize a specific endog-
enous substrate leads to this affliction. Perhaps this subject
(i.e., the real reason for the existence of DME genes and these
clinical polymorphisms) could have been used to replace the
naive chapter 4 of part I, or it could have been used as a third,
conclusion section.
All in all, however, this book is a worthwhile addition to
the shelves of all colleagues in the field. Pharmacogenetics
should serve, for the next several years, as an invaluable re-
source for helping to teach upper-level undergraduates, grad-
uate students, and other students of such health sciences as
medicine, pharmacy, and nursing.
DANIEL W. NEBERT
Center for Environmental Genetics
Departments of Environmental Health and Pediatrics
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The London Dysmorphology Database has been my favorite
syndromology search program for many years, but I have never
found it particularly easy to use. When I have been away from
it for a few weeks, I always seem to forget exactly which key
to push to make it do what I want. I was, therefore, anxious
to tear open the shrink-wrap on this new Windows imple-
mentation to see if my old friend was now friendlier.
The version of Oxford Medical Databases (OMD) that I
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tested includes two CD-ROMs and a brief (and not particularly
useful) manual. One CD-ROM contains the London Dys-
morphology Database and the London Neurogenetics Data-
base. The other CD-ROM includes 15,000 clinical photo-
graphs and radiographs that constitute the Photo Library, a
component that is essential for any clinical geneticist but that
must be purchased at additional cost.
The minimum system requirements are an industry-standard
personal computer with an 80486 DX33 or better CPU run-
ning Windows 3.1 or Windows 95, 4 MB of RAM (8 MB
is highly recommended), 83 MB of hard-disk space, a VGA
monitor (SVGA is highly recommended), a mouse, and a CD-
ROM drive. The program installed easily on my machine, a
133-Mhz Pentium with 16 MB of RAM and Windows 95.
OMD generally behaved well, although it interferes with some
DOS programs that are loaded after it.
The new version acts pretty much as a Windows program
should. This means that a user who is familiar with Windows
but has never seen OMD before can do searches and print the
resulting diagnosis lists, narrative summaries (“abstracts”),
and references without consulting the manual or the on-line
help. The printouts are nicely formatted, and one can modify
their appearance as well as their contents. Abstracts and in-
dividual references (but not feature lists or reference lists) can
be copied into other documents by means of the Windows
clipboard; photos cannot be printed or copied.
Version 2.0 of OMD does not do anything that the previous
DOS versions did not do, but everything is easier now that it
was before. The interface is much more attractive, and I found
some of the innovations to be very useful. For example, the
keyword search includes simple check boxes for microdele-
tions, disomy, and mosaicism as well as for Mendelian patterns
of inheritance. Tiny thumbnail photos adjacent to the syn-
drome abstract can be clicked to display full-size pictures of
particular features.
The contents of the databases are unchanged from earlier
versions, except for the addition of new information. OMD
includes an abstract, a list of reported features in the stan-
dardized language of the database, and an extensive bibliog-
raphy for each syndrome. The London Dysmorphology Da-
tabase has 12,800 different syndromes, and the London
Neurogenetics Database has 12,600, although there is much
overlap between the two. Neither database includes chromo-
somal abnormalities, except for the microdeletion syndromes
and some of the uniparental-disomy and chromosomal-mo-
saicism phenotypes. However, Oxford University Press also
distributes Albert Schinzel’s Human Cytogenetics Database, a
companion product that provides similar information on phe-
notypes associated with constitutional chromosomal
abnormalities.
The information in OMD is quite current to the time of
publication. There are many references from 1995 included,
and there are some from 1996 as well. In fact, the contents
seem more up to date than the software. Although this version
is well implemented in Windows, the system cries out for hy-
pertext links to the World Wide Web. OMD would be much
more powerful if the McKusick numbers were linked toOMIM
and if the gene locations were linked to the human gene maps
and the human/mouse homology database. Automatic updat-
ing of OMD over the Internet would also be a welcome
addition.
Will OMD replace the clinical geneticist? I doubt it. The
London Dysmorphology Database is an important diagnostic
aid, much like a radiograph or an electrocardiogram. The non-
specialist can obtain useful information from such aids, but
they are most valuable in the hands of the specialist. Consid-
erable skill is required to formulate an effective search in
OMD, and the clinical geneticist, who knows many genetic
syndromes by name, can weed through a list of possible di-
agnoses much more quickly than someone who is not familiar
with most of these conditions. Moreover, the clinical geneticist
is trained to recognize differences in gestalt that distinguish
between conditions with similar lists of phenotypic features.
The OMD’s Photo Library is of considerable assistance for
this purpose.
TheOxfordMedical Databases remain a valuable diagnostic
tool for clinical geneticists and a convenient source of current
bibliographic information on dysmorphic syndromes. The im-
provements in version 2.0’s interface make it much easier to
use than its predecessors. Information technology is advancing
as rapidly as genetics, however, and the next version of OMD
should be even better.
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